Tumor Angiogenesis Markers as Prognostic Factors in Advanced Cervical Cancer with Chemotherapy

I Nyoman Bayu Mahendra*  -  Universitas Udayana, Indonesia

(*) Corresponding Author
DOI: 10.30659/sainsmed.v15i2.28943

Cervical cancer or maligancy of the cervix is the second leading cause of cancer-related death in women worldwide. Despite improving screening and vaccine capacity, most patients still present at the health centre with severe manifestations or advanced stages and poor prognosis. Clinical evidence also shows that the sensitivities of various cervical cancer patients' chemotherapy regimens vary significantly, increasing the patient's risk of complications and leading to ineffective therapy. Thus, an effective molecular marker is needed that can accurately predict and estimate the patient's prognosis and response to therapy. Angiogenesis is one of main factors in the development and progression of solid tumours, including cervical cancer. Tumour angiogenesis markers, such as vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR), play an important role progression of advanced cervical cancer. Studies showed that VEGF levels significantly correlated with prognosis (tumour size and metastasis) and chemotherapy response in patients with advanced cervical cancer treated with chemotherapy. Therefore, tumour angiogenesis markers, such as VEGF and VEGFR, could be used as a prognostic factor in advanced cervical cancer with chemotherapy.

Keywords: advanced cervical cancer, chemotherapy, prognosis, VEGF, VEGFR

  1. Abdalla, D. R. et al. (2015) ‘Angiogenesis Markers in Gynecological Tumors and Patents for Anti-Angiogenic Approach: Review.’, Recent patents on anti-cancer drug discovery. United Arab Emirates, 10(3), pp. 298–307. doi: 10.2174/1574892810999150827153642.
  2. Apte, R. S., Chen, D. S. and Ferrara, N. (2019) ‘Review VEGF in Signaling and Disease : Beyond Discovery and Development’, Cell. Elsevier Inc., 176(6), pp. 1248–1264. doi: 10.1016/j.cell.2019.01.021.
  3. Baharara, J. et al. (2016) ‘Induction of Apoptosis by Green Synthesized Gold Nanoparticles Through Activation of Caspase-3 and 9 in Human Cervical Cancer Cells.’, Avicenna journal of medical biotechnology. Iran, 8(2), pp. 75–83.
  4. Barut, M. U. et al. (2015) ‘Analysis of Sensitivity, Specificity, and Positive and Negative Predictive Values of Smear and Colposcopy in Diagnosis of Premalignant and Malignant Cervical Lesions.’, Medical science monitor : international medical journal of experimental and clinical research. United States, 21, pp. 3860–3867. doi: 10.12659/msm.895227.
  5. Brisson, M. and Drolet, M. (2019) ‘Global elimination of cervical cancer as a public health problem.’, The Lancet. Oncology. England, 20(3), pp. 319–321. doi: 10.1016/S1470-2045(19)30072-5.
  6. Çakır, C. et al. (2021) ‘Neoadjuvant chemotherapy for locally advanced stage (IB2-IIA2-IIB) cervical carcinoma: Experience of a tertiary center and comprehensive review of the literature.’, Turkish journal of obstetrics and gynecology. Turkey, 18(3), pp. 190–202. doi: 10.4274/tjod.galenos.2021.70493.
  7. Choi, C. H. et al. (2008) ‘Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy’, BMC Cancer, 8, pp. 1–7. doi: 10.1186/1471-2407-8-295.
  8. Dang, Y. Z. et al. (2017) ‘High VEGFR1/2 expression levels are predictors of poor survival in patients with cervical cancer’, Medicine (United States), 96(1), pp. 1–6. doi: 10.1097/MD.0000000000005772.
  9. Du, K., Gong, H. Y. and Gong, Z. M. (2014) ‘Influence of serum vegf levels on therapeutic outcome and diagnosis/prognostic value in patients with cervical cancer’, Asian Pacific Journal of Cancer Prevention, 15(20), pp. 8793–8796. doi: 10.7314/APJCP.2014.15.20.8793.
  10. Eskander, R. N. and Tewari, K. S. (2014) ‘Targeting angiogenesis in advanced cervical cancer.’, Therapeutic advances in medical oncology. England, 6(6), pp. 280–292. doi: 10.1177/1758834014543794.
  11. Foran, C. and Brennan, A. (2015) ‘Prevention and early detection of cervical cancer in the UK.’, British journal of nursing (Mark Allen Publishing). England, 24(10), pp. S22-4, S26, S28-9. doi: 10.12968/bjon.2015.24.Sup10.S22.
  12. Gao, Y. et al. (2020) ‘Expression and prognosis of CyclinA and CDK2 in patients with advanced cervical cancer after chemotherapy’, Cellular and Molecular Biology, 66(3 SE-Original Research Articles), pp. 85–91. doi: 10.14715/cmb/2020.66.3.13.
  13. Kfouri, C. F. D. A. et al. (2019) ‘Prognostic factors for response to chemotherapy in advanced tumors of the uterine cervix: The role of neoangiogenesis’, Revista do Colegio Brasileiro de Cirurgioes, 46(1), pp. 1–10. doi: 10.1590/0100-6991e-20192077.
  14. Kurmyshkina, O. V et al. (2015) ‘Remodeling of angiogenesis and lymphangiogenesis in cervical cancer development.’, Biomeditsinskaia khimiia. Russia (Federation), 61(5), pp. 579–597. doi: 10.18097/PBMC20156105579.
  15. Li, W. et al. (2021) ‘Neoadjuvant Chemotherapy Followed by Surgery Versus Abdominal Radical Hysterectomy Alone for Oncological Outcomes of Stage IB3 Cervical Cancer—A Propensity Score Matching Analysis’, Frontiers in Oncology, 11(September), pp. 1–11. doi: 10.3389/fonc.2021.730753.
  16. Li, X. et al. (2022) ‘A Retrospective Study of Chemotherapy and 3D-Image-Guided Afterloading Intracavitary Radiotherapy in Locally Advanced Cervical Cancer’, Journal of Oncology, 2022. doi: 10.1155/2022/9578436.
  17. Liu, Y. et al. (2013) ‘Grading of uterine cervical cancer by using the ADC difference value and its correlation with microvascular density and vascular endothelial growth factor.’, European radiology. Germany, 23(3), pp. 757–765. doi: 10.1007/s00330-012-2657-1.
  18. Lv, Q. et al. (2018) ‘Expression of Angiopoietin and VEGF in Cervical Cancer and its Clinical Significance.’, Open life sciences. Poland, 13, pp. 527–532. doi: 10.1515/biol-2018-0063.
  19. Nwankwo, T. O. et al. (2020) ‘Impact of neoadjuvant chemotherapy in improving operative intervention in the management of cervical cancer in low resource setting: a preliminary report.’, The Pan African medical journal. Uganda, 36, p. 210. doi: 10.11604/pamj.2020.36.210.24141.
  20. Parida, S. et al. (2016) ‘GW627368X inhibits proliferation and induces apoptosis in cervical cancer by interfering with EP4/EGFR interactive signaling.’, Cell death & disease. England, 7(3), p. e2154. doi: 10.1038/cddis.2016.61.
  21. Patel, N. H. et al. (2020) ‘The Roles of Autophagy and Senescence in the Tumor Cell Response to Radiation.’, Radiation research. United States, 194(2), pp. 103–115. doi: 10.1667/RADE-20-00009.
  22. Pierre-Victor, D. et al. (2018) ‘Barriers to HPV Vaccination Among Unvaccinated, Haitian American College Women.’, Health equity. United States, 2(1), pp. 90–97. doi: 10.1089/heq.2017.0028.
  23. Pimple, S. A. and Mishra, G. A. (2019) ‘Global strategies for cervical cancer prevention and screening.’, Minerva ginecologica. Italy, 71(4), pp. 313–320. doi: 10.23736/S0026-4784.19.04397-1.
  24. Pinheiro, C. et al. (2015) ‘Reprogramming energy metabolism and inducing angiogenesis: co-expression of monocarboxylate transporters with VEGF family members in cervical adenocarcinomas’, BMC Cancer, 15(1), p. 835. doi: 10.1186/s12885-015-1842-4.
  25. Rahmani, A. H. et al. (2018) ‘Prognostic significance of vascular endothelial growth factor (VEGF) and Her-2 protein in the genesis of cervical carcinoma’, Open Access Macedonian Journal of Medical Sciences, 6(2), pp. 263–268. doi: 10.3889/OAMJMS.2018.089.
  26. Ramesh, A. et al. (2020) ‘Prevalence of Angiogenesis, Proliferation, and Apoptosis Markers of Cervical Cancer and Their Correlation with Clinicopathological Parameters’, Journal of Oncology. Edited by M. Aryan. Hindawi, 2020, p. 8541415. doi: 10.1155/2020/8541415.
  27. Rizzuto, I. et al. (2020) ‘Vascular endothelial growth factor (VEGF) inhibitors for the treatment of metastatic and recurrent cervical cancer.’, The Cochrane Database of Systematic Reviews. doi: 10.1002/14651858.CD013605.
  28. Sawada, M. et al. (2019) ‘Serum vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 as prognostic biomarkers for uterine cervical cancer’, International Journal of Clinical Oncology, 24(12), pp. 1612–1619. doi: 10.1007/s10147-019-01495-x.
  29. Scatchard, K. et al. (2013) ‘Chemotherapy for metastatic and recurrent cervical cancer.’, The Cochrane database of systematic reviews. England, 10(10), p. CD006469. doi: 10.1002/14651858.CD006469.pub2.
  30. Shang, Y. et al. (2020) ‘Management of critically ill patients with COVID-19 in ICU: statement from front-line intensive care experts in Wuhan, China’, Annals of Intensive Care, 10(1), p. 73. doi: 10.1186/s13613-020-00689-1.
  31. Tang, S. et al. (2021) ‘TMSB4 Overexpression Enhances the Potency of Marrow Mesenchymal Stromal Cells for Myocardial Repair.’, Frontiers in cell and developmental biology. Switzerland, 9, p. 670913. doi: 10.3389/fcell.2021.670913.
  32. Tian, Z.-Z. et al. (2014) ‘Investigation of uterine arterial chemoembolization and uterine arterial infusion chemotherapy for advanced cervical cancer before radical radiotherapy: a long-term follow-up study.’, Archives of gynecology and obstetrics. Germany, 290(1), pp. 155–162. doi: 10.1007/s00404-014-3166-z.
  33. Todo, Y. and Watari, H. (2016) ‘Concurrent chemoradiotherapy for cervical cancer: background including evidence-based data, pitfalls of the data, limitation of treatment in certain groups.’, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu. China, 28(2), pp. 221–227. doi: 10.21147/j.issn.1000-9604.2016.02.10.
  34. Tomao, F. et al. (2014) ‘Angiogenesis and antiangiogenic agents in cervical cancer.’, OncoTargets and therapy. New Zealand, 7, pp. 2237–2248. doi: 10.2147/OTT.S68286.
  35. Weng, D. et al. (2022) ‘Adjuvant chemotherapy versus adjuvant concurrent chemoradiotherapy after radical surgery for early-stage cervical cancer: a randomized, non-inferiority, multicenter trial.’, Frontiers of medicine. China, pp. 1–12. doi: 10.1007/s11684-021-0892-z.
  36. Yetkin-Arik, B. et al. (2021) ‘Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy’, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1875(1), p. 188446. doi: https://doi.org/10.1016/j.bbcan.2020.188446.
  37. Yoshida, K. et al. (2018) ‘The upregulated expression of vascular endothelial growth factor in surgically treated patients with recurrent/radioresistant cervical cancer of the uterus’, Oncol Lett. Department of Obstetrics and Gynecology, Graduate School of Medicine, Nagoya University, Showa‑ku, Nagoya 466‑8550, Japan Department of Obstetrics and Gynecology, Banbuntane Hotokukai Hospital, Nakagawa‑ku, Nagoya 454‑8509, Japan, 16(1), pp. 515–521. doi: 10.3892/ol.2018.8610.
  38. Zhang, S. et al. (2020) ‘Cervical cancer: Epidemiology, risk factors and screening.’, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu. China, 32(6), pp. 720–728. doi: 10.21147/j.issn.1000-9604.2020.06.05.
  39. Zhu, P. et al. (2016) ‘Expression of VEGF and HIF-1α in locally advanced cervical cancer: potential biomarkers for predicting preoperative radiochemotherapy sensitivity and prognosis.’, OncoTargets and therapy. New Zealand, 9, pp. 3031–3037. doi: 10.2147/OTT.S104142.
  40. Zhu, P. F. et al. (2016) ‘Expression of VEGF and HIF-Iα in locally advanced cervical cancer: Potential biomarkers for predicting preoperative radiochemotherapy sensitivity and prognosis’, OncoTargets and Therapy, 9, pp. 3031–3037. doi: 10.2147/OTT.S104142.
  41. Zuo, Y. et al. (2013) ‘Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis’, Kidney International, 84(6), pp. 1166–1175. doi: https://doi.org/10.1038/ki.2013.209.

Open Access Copyright (c) 2024 Sains Medika : Jurnal Kedokteran dan Kesehatan
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Sains Medika: Jurnal Kedokteran dan Kesehatan
is published by Faculty of Medicine Universitas Islam Sultan Agung, Indonesia in association with FOKI (FORUM KEDOKTERAN ISLAM INDONESIA).

Contact: Jl. Raya Kaligawe Km.4, PO BOX 1054/SM Semarang 50112, Indonesia
Phone: +62 8122-9933-369
Website: https://fkunissula.ac.id
Email: sainsmedika@unissula.ac.id

ISSN: 2339-093X (Online) | 2085-1545 (Print)
DOI : 10.30659/sainsmed

This work is licensed under a Creative Commons Attribution 4.0 International License

Get a feed by atom here, RRS2 here and OAI Links here

apps